Literature DB >> 24990263

(89)Zr-labeled compounds for PET imaging guided personalized therapy.

Danielle J Vugts1, Guus A M S van Dongen2.   

Abstract

(89)Zr-immuno-PET is an attractive option for the in vivo evaluation of monoclonal antibodies (mAbs). For the coupling of (89)Zr to monoclonal antibodies several conjugation strategies are available all using desferrioxamine as chelate. Here we discuss the production of (89)Zr, the available methods for coupling of (89)Zr via desferrioxamine to mAbs, and the evaluation of (89)Zr-mAb conjugates in preclinical and clinical studies.:
© 2011 Published by Elsevier Ltd.

Entities:  

Year:  2011        PMID: 24990263     DOI: 10.1016/j.ddtec.2011.12.004

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  13 in total

1.  Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.

Authors:  Brendon E Cook; Pierre Adumeau; Rosemery Membreno; Kathryn E Carnazza; Christian Brand; Thomas Reiner; Brian J Agnew; Jason S Lewis; Brian M Zeglis
Journal:  Bioconjug Chem       Date:  2016-07-14       Impact factor: 4.774

Review 2.  PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Authors:  Melissa A Deri; Brian M Zeglis; Lynn C Francesconi; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2012-09-19       Impact factor: 2.408

3.  The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  J Vis Exp       Date:  2015-02-12       Impact factor: 1.355

4.  Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.

Authors:  Brian M Zeglis; Christian Brand; Dalya Abdel-Atti; Kathryn E Carnazza; Brendon E Cook; Sean Carlin; Thomas Reiner; Jason S Lewis
Journal:  Mol Pharm       Date:  2015-08-31       Impact factor: 4.939

5.  Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry.

Authors:  Brian M Zeglis; Charles B Davis; Robert Aggeler; Hee Chol Kang; Aimei Chen; Brian J Agnew; Jason S Lewis
Journal:  Bioconjug Chem       Date:  2013-05-30       Impact factor: 4.774

6.  p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.

Authors:  Melissa A Deri; Shashikanth Ponnala; Paul Kozlowski; Benjamin P Burton-Pye; Huseyin T Cicek; Chunhua Hu; Jason S Lewis; Lynn C Francesconi
Journal:  Bioconjug Chem       Date:  2015-11-25       Impact factor: 4.774

Review 7.  Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects.

Authors:  Sijumon Kunjachan; Josef Ehling; Gert Storm; Fabian Kiessling; Twan Lammers
Journal:  Chem Rev       Date:  2015-07-13       Impact factor: 60.622

8.  Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B.

Authors:  Michelle T Ma; Levente K Meszaros; Brett M Paterson; David J Berry; Maggie S Cooper; Yongmin Ma; Robert C Hider; Philip J Blower
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

Review 9.  Immuno-PET for Clinical Theranostic Approaches.

Authors:  Clément Bailly; Pierre-François Cléry; Alain Faivre-Chauvet; Mickael Bourgeois; François Guérard; Ferid Haddad; Jacques Barbet; Michel Chérel; Françoise Kraeber-Bodéré; Thomas Carlier; Caroline Bodet-Milin
Journal:  Int J Mol Sci       Date:  2016-12-28       Impact factor: 5.923

10.  Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).

Authors:  Melissa A Deri; Shashikanth Ponnala; Brian M Zeglis; Gabor Pohl; J J Dannenberg; Jason S Lewis; Lynn C Francesconi
Journal:  J Med Chem       Date:  2014-05-19       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.